Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 102021, 13 pages
http://dx.doi.org/10.1155/2015/102021
Research Article

Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4+ T Cells

1Department of Traditional Chinese Medicine, Second Clinical Medical College, Guangdong Medical College, Dongguan 523808, China
2China-America Cancer Research Institute, Guangdong Medical College, Dongguan 523808, China
3Second Clinical Medical College, Guangdong Medical College, Dongguan 523808, China

Received 12 October 2014; Accepted 11 December 2014

Academic Editor: Wei-Chien Huang

Copyright © 2015 Ying Zou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Kaser, S. Zeissig, and R. S. Blumberg, “Inflammatory bowel disease,” Annual Review of Immunology, vol. 28, pp. 573–621, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Xavier and D. K. Podolsky, “Unravelling the pathogenesis of inflammatory bowel disease,” Nature, vol. 448, no. 7152, pp. 427–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Antignano, K. Burrows, M. R. Hughes et al., “Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation,” The Journal of Clinical Investigation, vol. 124, no. 5, pp. 1945–1955, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. C. L. Maynard and C. T. Weaver, “Intestinal effector T cells in health and disease,” Immunity, vol. 31, no. 3, pp. 389–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Zhu, H. Yamane, and W. E. Paul, “Differentiation of effector CD4 T cell populations*,” Annual Review of Immunology, vol. 28, pp. 445–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. A. Fouser, J. F. Wright, K. Dunussi-Joannopoulos, and M. Collins, “Th17 cytokines and their emerging roles in inflammation and autoimmunity,” Immunological Reviews, vol. 226, no. 1, pp. 87–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. D'Haens, “Risk and benefits of biologic therapy for inflammatory bowel diseases,” Gut, vol. 56, no. 5, pp. 725–732, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. H. Holtmann, A.-L. Gerts, A. Weinman, P. R. Galle, and M. F. Neurath, “Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety,” Digestive Diseases and Sciences, vol. 53, no. 4, pp. 1025–1032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Baert, S. Vermeire, M. Noman, G. van Assche, G. D'Haens, and P. Rutgeerts, “Management of ulcerative colitis and Crohn's disease,” Acta Clinica Belgica, vol. 59, no. 5, pp. 304–314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-H. Liu and Y.-C. Cheng, “Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy,” Journal of Ethnopharmacology, vol. 140, no. 3, pp. 614–623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk, and J. L. Wallace, “Hapten-induced model of chronic inflammation and ulceration in the rat colon,” Gastroenterology, vol. 96, no. 3, pp. 795–803, 1989. View at Google Scholar · View at Scopus
  13. R. Glauben, A. Batra, T. Stroh et al., “Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice,” Gut, vol. 57, no. 5, pp. 613–622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. J. Bell, D. G. Gall, and J. L. Wallace, “Disruption of colonic electrolyte transport in experimental colitis,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 268, no. 4, pp. G622–G630, 1995. View at Google Scholar · View at Scopus
  15. L. A. Dieleman, M. J. H. J. Palmen, H. Akol et al., “Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines,” Clinical & Experimental Immunology, vol. 114, no. 3, pp. 385–391, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. J. E. Krawisz, P. Sharon, and W. F. Stenson, “Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models,” Gastroenterology, vol. 87, no. 6, pp. 1344–1350, 1984. View at Google Scholar · View at Scopus
  17. A. Okazawa, T. Kanai, M. Watanabe et al., “Th1-mediated intestinal inflammation in Crohn's disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement,” The American Journal of Gastroenterology, vol. 97, no. 12, pp. 3108–3117, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, and C. L. Yan, “Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 41, pp. 15896–15901, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Zhang, M. Zheng, J. Bindas, P. Schwarzenberger, and J. K. Kolls, “Critical role of IL-17 receptor signaling in acute TNBS-induced colitis,” Inflammatory Bowel Diseases, vol. 12, no. 5, pp. 382–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Takeshima, M. Matsumura, K. Makiyama et al., “Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis,” Medical Science Monitor, vol. 20, pp. 1314–1318, 2014. View at Google Scholar
  21. C. O. Elson, R. B. Sartor, G. S. Tennyson, and R. H. Riddell, “Experimental models of inflammatory bowel disease,” Gastroenterology, vol. 109, no. 4, pp. 1344–1367, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. N. E. Ruyssers, B. Y. de Winter, J. G. de Man et al., “Therapeutic potential of helminth soluble proteins in TNBS induced colitis in mice,” Inflammatory Bowel Diseases, vol. 15, no. 4, pp. 491–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. S. J. Probert, A. U. Dignass, S. Lindgren, M. Oudkerk Pool, and P. Marteau, “Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life,” Journal of Crohn's and Colitis, vol. 8, no. 3, pp. 200–207, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Pawar, S. Gilda, S. Sharma et al., “Rectal gel application of Withania somnifera root extract expounds anti-inflammatory and muco-restorative activity in TNBS-induced Inflammatory Bowel Disease,” BMC Complementary and Alternative Medicine, vol. 11, article 34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. D. DeBoer, J. Steinman, and Y. Li, “Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody,” Journal of Gastroenterology, vol. 47, no. 6, pp. 647–654, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Dionne, J. Hiscott, I. D'Agata, A. Duhaime, and E. G. Seidman, “Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies,” Digestive Diseases and Sciences, vol. 42, no. 7, pp. 1557–1566, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. L. A. Zenewicz, A. Antov, and R. A. Flavell, “CD4 T-cell differentiation and inflammatory bowel disease,” Trends in Molecular Medicine, vol. 15, no. 5, pp. 199–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Niessner and B. A. Volk, “Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR),” Clinical and Experimental Immunology, vol. 101, no. 3, pp. 428–435, 1995. View at Google Scholar · View at Scopus
  29. A. Bai, N. Lu, H. Zeng et al., “All-trans retinoic acid ameliorates trinitrobenzene sulfonic acid-induced colitis by shifting Th1 to Th2 profile,” Journal of Interferon & Cytokine Research, vol. 30, no. 6, pp. 399–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. L. A. Fouser, J. F. Wright, K. Dunussi-Joannopoulos, and M. Collins, “Th17 cytokines and their emerging roles in inflammation and autoimmunity,” Immunological Reviews, vol. 226, no. 1, pp. 87–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Gálvez, “Role of Th17 cells in the pathogenesis of human IBD,” ISRN Inflammation, vol. 2014, Article ID 928461, 14 pages, 2014. View at Publisher · View at Google Scholar
  32. T. Olsen, R. Rismo, G. Cui, R. Goll, I. Christiansen, and J. Florholmen, “TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation,” Cytokine, vol. 56, no. 3, pp. 633–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Gibson, E. J. Ryan, and G. A. Doherty, “Keeping the bowel regular: the emerging role of treg as a therapeutic target in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 19, no. 12, pp. 2716–2724, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Maul, C. Loddenkemper, P. Mundt et al., “Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease,” Gastroenterology, vol. 128, no. 7, pp. 1868–1878, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Roselli, A. Finamore, S. Nuccitelli et al., “Prevention of TNBSinduced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of γδT and regulatory T cells of intestinal intraepithelial lymphocytes,” Inflammatory Bowel Diseases, vol. 15, no. 10, pp. 1526–1536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Read, V. Malmström, and F. Powrie, “Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+ CD4+ regulatory cells that control intestinal inflammation,” The Journal of Experimental Medicine, vol. 192, no. 2, pp. 295–302, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Strober and I. J. Fuss, “Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 6, pp. 1756–1767, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. C. Gomes-Santos, T. G. Moreira, A. B. Castro-Junior et al., “New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa,” Clinical and Developmental Immunology, vol. 2012, Article ID 560817, 13 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Yin, X. Li, B. Zhang et al., “Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis,” Immunology, vol. 139, no. 4, pp. 494–502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Duan, J. Chen, H. Zhang et al., “Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3+ regulatory T-cell responses in mice,” Molecular Medicine, vol. 18, no. 5, pp. 753–761, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. F. Neurath, B. Weigmann, S. Finotto et al., “The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease,” Journal of Experimental Medicine, vol. 195, no. 9, pp. 1129–1143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Daniel, N. A. Sartory, N. Zahn, H. H. Radeke, and J. M. Stein, “Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 1, pp. 23–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S.-H. Fu, M.-H. Lin, L.-T. Yeh et al., “Targeting tumour necrosis factor receptor 1 assembly reverses Th17-mediated colitis through boosting a Th2 response,” Gut, 2014. View at Publisher · View at Google Scholar
  46. E. M. Shevach, “Biological functions of regulatory T cells,” Advances in Immunology, vol. 112, pp. 137–176, 2011. View at Publisher · View at Google Scholar · View at Scopus